Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Dec 8 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

How is AI and data leadership at large organizations being transformed by the accelerating pace of AI adoption? Do these leaders’ mandates need to change? And should overseeing AI and data be viewed ...

Silicon Valley entrepreneurs prefer to talk of possibilities rather than obstacles, and of vast revenue opportunities to be seized through sheer force of will. That defiant optimism now faces the ...

Data is the oil that fuels the AI gold rush; machines need it to understand the world and help us solve its most pressing problems. But the way we use, collect and store data is evolving as quickly as ...

The amount of capital pouring into AI data center projects is staggering. Last week, Microsoft, Alphabet, Meta, and Amazon reported their 2025 capital expenditures would total roughly $370 billion, ...

Artificial intelligence has developed rapidly in recent years, with tech companies investing billions of dollars in data centers to help train and run AI models. The expansion of data centers has ...

Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...